Safety of Diabetes Drugs

Two studies published in professional journals this year have cast renewed doubt about the safety of one of our most important class of diabetes drugs. But the leading regulatory agencies both in Europe and the U.S. seem to think that those studies are flawed. We call this class of drugs incretin-based or GLP-1 agonists. They include Byetta, Victoza, and Bydureon. The most recent investigation of this class of drugs came out last month...
Source: David Mendosa's SharePosts - Category: Diabetes Authors: Source Type: blogs